Total submissions: 8
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Center for Genomic Medicine, |
RCV004668963 | SCV005094443 | oncogenic | Neoplasm | 2025-03-04 | criteria provided, single submitter | clinical testing | |
| Myriad Genetics, |
RCV002289541 | SCV004932383 | likely pathogenic | Li-Fraumeni syndrome 1 | 2024-02-14 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 8631304, 10229196, 23246812]. |
| Ambry Genetics | RCV002289542 | SCV002644142 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-03-25 | criteria provided, single submitter | clinical testing | The p.V173L pathogenic mutation (also known as c.517G>T), located in coding exon 4 of the TP53 gene, results from a G to T substitution at nucleotide position 517. The valine at codon 173 is replaced by leucine, an amino acid with highly similar properties. This variant is in the DNA binding domain of the TP53 protein and is reported to have non-functional transactivation in yeast based assays (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9). Studies conducted in human cell lines indicate this alteration is deficient at growth suppression and has a dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). Another alteration at the same codon, p.V173M (c.517G>A), has been detected in a family meeting clinical criteria for Li-Fraumeni Syndrome (Achatz M et al. Cancer Lett. 2007 Jan; 245(1-2):96-102). This alteration has been observed numerous times as a somatic mutation in the cancerhotspots.org database (Chang MT et al. Cancer Discov. 2018 02;8:174-183). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Genome- |
RCV002289541 | SCV002583049 | likely pathogenic | Li-Fraumeni syndrome 1 | 2022-06-18 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV002289542 | SCV002582387 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-18 | criteria provided, single submitter | clinical testing | |
| Genetic Services Laboratory, |
RCV001821147 | SCV002065920 | likely pathogenic | not provided | 2022-01-14 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the TP53 gene demonstrated a sequence change, c.517G>T, in exon 5 that results in an amino acid change, p.Val173Leu. The p.Val173Leu change affects a highly conserved amino acid residue located in a domain of the TP53 protein that is known to be functional. The p.Val173Leu substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change has not previously been described in individuals with Li-Fraumeni syndrome, however, the p.Val173Leu amino acid change occurs in a region of the TP53 gene where other missense sequence changes (p.Val173Met, Val173Ala) have been described in individuals with TP53-related disorders (PMID: 21343334, 29070607). Experimental studies have demonstrated that this sequence change impacts the function of the TP53 protein (PMID: 20407015, 16474844, 12826609, 9407971, 23967324) and this residue is located in a well-established functional domain (PMID: 29099487). Based on this evidence, this sequence change is classified as likely pathogenic. |
| Labcorp Genetics |
RCV000694763 | SCV000823221 | pathogenic | Li-Fraumeni syndrome | 2025-05-23 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 173 of the TP53 protein (p.Val173Leu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 376668). Invitae Evidence Modeling incorporating data from in vitro experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is expected to disrupt TP53 function with a positive predictive value of 97.5%. Experimental studies have shown that this missense change affects TP53 function (PMID: 9407971, 12826609, 16474844, 20407015, 23967324). This variant disrupts the p.Val173 amino acid residue in TP53. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12826609, 21343334; internal data). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| German Consortium for Hereditary Breast and Ovarian Cancer, |
RCV000785539 | SCV000924111 | likely pathogenic | Ovarian neoplasm | 2018-12-01 | no assertion criteria provided | research |